The pharmaceutical company’s net profit fell by 84.2% year-on-year in Q2, dropping to Rs 27.1 crore from Rs 172 crore in the same quarter last year. Operational performance also weakened, with the EBITDA margin decreasing to 19% in Q2, down from 21% during the same period last year.
However, despite the decline in profit and operational performance, the company’s revenue from operations rose by 3.7% to Rs 3,590.4 crore, compared to Rs 3,462 crore in Q2 of FY24.
Price as on 11.19.08 AM, Click on company names for their live prices.